TerminatedPhase 4

A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia

Stopped: Due to administrative reasons

China59 participantsStarted 2013-09-26

Plain-language summary

To evaluate the efficacy and safety of intravenous micafungin for the treatment of patients with proven or probable fungal infections caused by Candida sp. (Fungemia, respiratory mycosis, gastrointestinal mycosis) in adult patients in China.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Risk factor (s) of infection
✓. Clinical manifestations of infection and the pulmonary infection cannot be explained by other pathogenic infections
✓. Two or more positive sputum culture for Candida

What they're measuring

Overall success rate

Timeframe: up to 8 weeks

Trial details

NCT IDNCT01982071

SponsorAstellas Pharma China, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-08-28

View on ClinicalTrials.gov More Candidemia trials